News >

Markman Outlines Biosimilars and Cost-Effective Oncology Practices

Brandon Scalea
Published: Thursday, Dec 13, 2018

Maurie Markman, MD

Maurie Markman, MD
The rising cost of oncology treatments is a natural result of the rapid advancements in the field, said Maurie Markman, MD. However, he added, unless it is addressed quickly, patients will not be able to access the therapy they need.

, Markman discussed the evolution of biosimilars and ongoing efforts to make treatments more affordable for patients with cancer.

OncLive: What is your opinion on the use of biosimilars?

Markman: Biosimilars are a very interesting concept. Obviously, at the highest level, you look at them and say, "Wow, they will really lower the cost of expensive drugs." It's like “mom and apple pie”—how could you possibly disagree with that? However, I understand that biosimilars are not the same as small-molecule generic drugs. Safety and efficacy are obviously critical endpoints, but based on the additional data we have seen so far, we are not seeing much cost reduction yet. I couldn't tell you the reason why that is, because I am not an economist. 
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication